Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZDFRI)

• Drug Name: Acanthus ilicifolius Linn Drug Info
• Synonyms: AC1L1B2B; CBiol_001885; KBioGR_000483; KBioSS_000483; BSPBio_001143; (-)-Huperzine A-d5 (Major); CHEMBL3184073; KBio3_000886; CTK8E6796; KBio2_003051; BDBM10441; KBio2_005619; KBio2_000483; KBio3_000885; Bio2_000402; Bio1_001149; Bio1_000660; HMS1990I05; Bio2_000882; Bio1_000171; AKOS032962044; AN-1052; KS-0000000G; IDI1_002157; NCGC00163246-01; FT-0642946; N1881; Acarviostatin III03; Acarviostatin IV03

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1253
  CAS Number: CAS 102518-79-6
  TTD Drug ID: DMZDFRI

Molecule-Related Drug Atlas

Drug(s) Targeting Arachidonate 5-lipoxygenase (5-LOX)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[3]
Diethylcarbamazine	DM1TJ8F	Elephantiasis		Approved	[4]
Silymarin	DMXBYQR	N. A.	N. A.	Phase 4	[5]
3,4-Dihydroxycinnamic Acid	DMVZL26	Thrombocytopenia	3B64	Phase 4	[6]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
ABT-761	DM3FIC2	Asthma	CA23	Phase 3	[8]
Tenidap	DMHQRYE	Rheumatoid arthritis	FA20	Phase 3	[9]
FPL-62064	DMGF8MZ	Inflammation	1A00-CA43.1	Phase 3	[10]
Flobufen	DMPSG4D	Rheumatoid arthritis	FA20	Phase 3	[11]
Darbufelone	DMYVKM5	Asthma	CA23	Phase 2/3	[12]

Drug(s) Targeting Pancreatic alpha-amylase (AMY2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[13]
Liprotamase	DMNF4UH	Cystic fibrosis	CA25	Phase 3	[14]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[15]
Pyroglutamic Acid	DMROZUA	Discovery agent	N.A.	Investigative	[15]
6-Deoxy-Alpha-D-Glucose	DM9HBY5	Discovery agent	N.A.	Investigative	[15]
Acarbose Derived Hexasaccharide	DMS9COH	Discovery agent	N.A.	Investigative	[15]
Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam	DMMY542	Discovery agent	N.A.	Investigative	[16]
Hydroxycitric acid	DMY0A9E	Discovery agent	N.A.	Investigative	[17]
Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen	DM4IXUQ	Discovery agent	N.A.	Investigative	[18]
Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen	DMHV14R	Discovery agent	N.A.	Investigative	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Arachidonate 5-lipoxygenase (5-LOX)	TT2J34L	LOX5_HUMAN	Inhibitor	[1]
Pancreatic alpha-amylase (AMY2A)	TTCGSZ4	AMYP_HUMAN	Inhibitor	[2]

References

• [1] Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12.
• [2] Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92.
• [3] 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52.
• [4] Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7.
• [5] Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4.
• [6] Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6.
• [7] Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80.
• [8] Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307.
• [9] The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3.
• [10] FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42.
• [11] Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52.
• [12] Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9.
• [13] Clinical pipeline report, company report or official report of Digestive Care.
• [14] Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
• [15] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [16] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [17] Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82.
• [18] Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30.